

Figure 1




Figure 2





Figure 3



4/177





Figure 4



Figure 5






Figure 6

Figure 7




Figure 8





Figure 9






Figure 11




Figure 12






Figure 13




Figure 14




Figure 15




Figure 16




Figure 17




Figure 18




Figure 19




Figure 20






Figure 21




Figure 22




Figure 23




Figure 24




Figure 25




Figure 26






Figure 27



## Figure 28





## Figure 29




Figure 30





Figure 31






Figure 33




Figure 34






Figure 35



36/177


Figure 36a






37/177

Figure 36b



38/177

Figure 37



39/177





Figure 37 (continued)



41/177

Figure 39




Figure 40




Figure 41




Figure 42







Figure 43






Figure 44

Figure 45




Figure 46






Figure 47



50/177

Figure 48


Local Reactions, by Maximum Severity, Within 7 Days After Each Dose – Safety Population – Stage 1, 2 Dose, 21 Days Apart – 18-55 Years of Age – BNT162b1



Note: Number above each bar denotes percentage of participants reporting the event with any severity.


Figure 49

Systemic Events, by Maximum Severity, Within 7 Days After Each Dose – Safety Population – Stage 1, 2 Dose, 21 Days Apart – 18-55 Years of Age – BNT162b1



Note: Severity was not collected for use of antipyretic or pain medication.  
Note: Number above each bar denotes percentage of participants reporting the event with any severity.


Figure 50



Note: Dot presents individual antibody levels.  
Note: Number within each bar denotes geometric mean.




Figure 51



54/177

Figure 52


Local Reactions, by Maximum Severity, Within 7 Days After Each Dose – Safety Population –  
Stage 1, 2 Dose, 21 Days Apart – 18-55 Years of Age – BNT162b2



Note: Number above each bar denotes percentage of participants reporting the event with any severity.

Figure 53


Systemic Events, by Maximum Severity, Within 7 Days After Each Dose – Safety Population – Stage 1, 2 Dose, 21 Days Apart – 18-55 Years of Age – BNT162b2



Note: Severity was not collected for use of antipyretic or pain medication.  
Note: Number above each bar denotes percentage of participants reporting the event with any severity

56/177

Figure 54



57/177

Figure 55

Systemic Events, by Maximum Severity, Within 7 Days After Each Dose – Safety Population – Stage 1, 2 Dose, 21 Days Apart – 65-85 Years of Age – BNT162b2






Figure 56



Note: Dot presents individual antibody levels.  
Note: Number within each bar denotes geometric mean.

Figure 57


Geometric Mean and 95% CI: SARS-CoV-2 Serum Neutralizing Titer 50 –  
All-Available Immunogenicity Population – Stage 1, 2 Dose, 21 Days Apart – 18-55 Years of Age – BNT162b2



Note: Dot presents individual antibody levels.  
Note: Number within each bar denotes geometric mean.

Figure 58

Geometric Mean and 95% CI: SARS-CoV-2 Anti-S1 Binding Antibody Levels –  
All-Available Immunogenicity Population – Stage 1, 2 Dose, 21 Days Apart – 65-85 Years of Age – BNT162b2




Note: Dot presents individual antibody levels.  
Note: Number within each bar denotes geometric mean.



Figure 59


Geometric Mean and 95% CI: SARS-CoV-2 Serum Neutralizing Titer 50 – All-Available Immunogenicity Population – Stage 1, 2 Dose, 21 Days Apart – 65-85 Years of Age – BNT162b2



Note: Dot presents individual antibody levels.  
Note: Number within each bar denotes geometric mean.

62/177

Figure 60



63/177





Figure 61

64/177

Figure 62






Figure 64




Figure 65




Figure 66






Figure 67




Figure 68







Figure 69



72/177

Figure 70





## Figure 71

74/177





Figure 71 (continued)


75/177

Figure 72



76/177


Figure 73






77/177

Figure 74




78/177

Figure 75



79/177

Figure 76



80/177

Figure 77






Figure 78



82/177

Figure 79



83/177

Figure 80




Figure 81






Figure 82




Figure 83




Figure 84




Figure 85




Figure 86




Figure 87





Figure 88



Note: Number above each bar denotes percentage of participants reporting the event with any severity.

Figure 89






Figure 90




Figure 91




Figure 92




Figure 93




Figure 94




Figure 95




Figure 96




Figure 97






Figure 98




Figure 99

Systemic Events, by Maximum Severity, Within 7 Days After Each Dose – ~6000 Subjects for Phase 2/3 Analysis – Safety Population  
Age Group: 56-85 Years





Figure 100



104/177




Figure 101

Figure 102





Figure 103



107/177




Figure 104

108/177





Figure 105




Figure 106



110/177

Figure 107



111/177






Figure 108

112/177

Figure 109



## Figure 110



114/177




Figure 111

Figure 112

a





Figure 112

**b**



**c**






Figure 113




Figure 113





Figure 114




Figure 115




Figure 115





Figure 115

d



### Figure 116

८





Figure 116





125/177




Figure 117

Figure 118




Figure 119




Figure 120





Figure 120

B



130/177

Figure 120





Figure 121



132/177




Figure 122






Figure 123

Figure 124




Figure 125





Figure 126



137/177




Figure 127

Figure 128






Figure 129




140/177



**Figure 130**



Figure 131







Figure 133



144/177

Figure 134





Figure 135



146/177





Figure 136

Figure 137






Figure 138



149/177




Figure 139

Figure 140





Figure 141



152/177





Figure 142

Figure 143

IHC-ISH, modRNA-V9, draining LN, 6h, T20-0148






Figure 144

Figure 145




Figure 146






Figure 147








Figure 148

FEFCO 0201



FEFCO 0204



159/177





Figure 149




FEFCO 0426



161/177

Figure 151



162/177

Figure 152






Figure 153



Edge vials



Center vials





Figure 154

Thawing profile during 5 min walk





165/177

Figure 155




Figure 156



Figure 157






Figure 158


Configuration B




i)



ii)



iii)




229

iv)


169/177

Figure 159


Configuration C/D




i)



ii)



iii)




iv)


170/177

Figure 160


Configuration E




i)



ii)




iii)



iv)


Figure 161




172/177

Figure 162


Configuration G




i)



iii)



ii)




iv)




Figure 163


Configuration H




i)



ii)






iii)



iv)

Figure 164


Configuration I




175/177

Figure 165

Configuration J



i)



iii)




Figure 166

Configuration K




Figure 167

Configuration L

